Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage
Authors:
- 1 June 2009
- journal article
- research article
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 15 (3) , 184-188
Abstract
To observe the therapeutic efficacy of Danggui Buxue Decoction No.1 (当归补血汤1号, DB1) in treating patients of non-small cell lung cancer (NSCLC) at the peri-operational stage and its impact on the patients’ immune function.Keywords
This publication has 7 references indexed in Scilit:
- Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cellsLung Cancer, 2007
- Prediction of anti-tumour effect of thermochemotherapy within vitrothermochemosensitivity testing for non-small cell lung cancerInternational Journal of Hyperthermia, 2007
- The role of regulatory T cells in the control of natural killer cells: relevance during tumor progressionImmunological Reviews, 2006
- Molecular Mechanism of NFAT Family Proteins for Differential Regulation of the IL-2 and TNF-α PromotersMolecules and Cells, 2002
- Concomitant Administration of Interleukin-2 Plus Tumor Necrosis Factor in Advanced Non-Small Cell Lung CancerAmerican Journal of Clinical Oncology, 1995
- Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1British Journal of Cancer, 1994
- Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.1993